Bio-Rad Laboratories

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostics for early cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in laboratory-developed tests, including DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a gene expression-based test. It also focuses on DetermaDx, a blood-based test for lung cancer detection, and is working on diagnostics for bladder and breast cancers. OncoCyte aims to provide actionable insights to healthcare providers and patients, enhancing decision-making in cancer care while striving to improve patient outcomes and lower healthcare costs. The company has formed strategic collaborations to facilitate comprehensive solutions for pharmaceutical clients, encompassing patient recruitment and regulatory approvals.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostics for early cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in laboratory-developed tests, including DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a gene expression-based test. It also focuses on DetermaDx, a blood-based test for lung cancer detection, and is working on diagnostics for bladder and breast cancers. OncoCyte aims to provide actionable insights to healthcare providers and patients, enhancing decision-making in cancer care while striving to improve patient outcomes and lower healthcare costs. The company has formed strategic collaborations to facilitate comprehensive solutions for pharmaceutical clients, encompassing patient recruitment and regulatory approvals.

Curiosity Diagnostics is a pre-commercial platform company specializing in digital PCR systems for point-of-care applications. The company has developed PCR|ONE, a versatile diagnostic platform that enables the creation of customized, cost-effective assay panels for various pathogens, including MRSA and SARS-CoV-2. This system allows for rapid expansion and adaptation of diagnostic panels, addressing evolving public health needs and epidemiological threats. By focusing on user-specific solutions, Curiosity Diagnostics aims to enhance the accessibility and efficiency of diagnostic testing in diverse healthcare settings.

Dropworks, Inc., based in Phoenix, Arizona, specializes in developing innovative digital PCR technology called FluxPCR. This technology utilizes continuous flow droplet nanoreactors to provide absolute quantification and ultra-high sensitivity for DNA and RNA analysis. Dropworks' approach offers a simple workflow, high throughput, and low cost, making it more efficient than traditional qPCR methods. The company's integrated microfluidic technology enables portable molecular biology laboratories, facilitating rapid diagnostic applications and personalized medicine through cancer genotyping. Dropworks aims to revolutionize research and clinical settings by enabling the swift development of drugs and biomarkers, as well as enhancing point-of-care diagnostics and viral load quantification.

Celsee Diagnostics (formerly DeNovo Sciences) mission is to provide an easy to use platform for cancer research and diagnosis. Specifically, the company will sell an instrument system and reagent kit that allows for the separation, detection, and retrieval of circulating tumor cells (CTCs) from peripheral whole blood as an alternative to traditionally painful and invasive biopsies. Their company is developing a proprietary product that will not only allow researchers to identify and capture rare and difficult to harvest cancer cells in a microfluidic chip but also enable them to conduct downstream molecular analysis. This technology allows for the development of personalized therapies as well as the ability to monitor patient prognosis.

RainDance Technologies, Inc. specializes in developing advanced genomic tools for non-invasive liquid biopsy applications, focusing on cancer detection, treatment, and the study of inherited and infectious diseases. The company's flagship product, the RainDrop digital polymerase chain reaction platform, utilizes picoliter-sized droplets to facilitate multiplex detection of genetic material, including DNA and RNA. Additionally, RainDance offers the RainDrop Plus digital PCR system, which integrates next-generation sequencing (NGS) amplicon enrichment with digital PCR capabilities. Their automated ThunderStorm solution enhances NGS content enrichment, allowing laboratories to process multiple samples efficiently while ensuring high-quality data. The ThunderBolts panels target critical cancer mutations and specific genetic markers associated with myeloid disorders. RainDance's products include a range of consumables designed to optimize various laboratory processes. Founded in 2004 and headquartered in Billerica, Massachusetts, the company serves research institutions and laboratories globally through a network of sales representatives and distributors. RainDance Technologies operates as a subsidiary of Bio-Rad Laboratories, Inc.

Oxford Impedance Diagnostics Limited is a company based in Oxford, United Kingdom, that focuses on researching, designing, and marketing diagnostic tests specifically aimed at measuring clinical biomarkers. Founded in 2016, the company's products are intended to facilitate personalized medicine, enhance early risk detection, and improve the diagnosis and management of diseases. By providing innovative diagnostic solutions, Oxford Impedance Diagnostics seeks to reduce healthcare costs while improving patient outcomes.

GnuBIO is a developer of innovative DNA sequencing technology tailored for diagnostic and applied markets. The company employs emulsion-based microfluidic technology to create a scalable desktop sequencing system capable of analyzing single genes, gene panels, and whole genomes. GnuBIO's proprietary platform integrates all essential steps of DNA sequencing, including target selection, enrichment, amplification, sequencing, and analysis, into a single user-friendly interface. This streamlined process significantly reduces the time required to obtain results, delivering them in hours instead of days, thereby enhancing the efficiency of research and clinical laboratories. GnuBIO's approach facilitates customized experimental designs, catering to the specific needs of clinicians and researchers.

For 30 years, AbD Serotec has been one of the world leaders in antibody production, supplying thousands of catalog antibodies, kits and accessories to scientific researchers requiring products from dendritic cell antibodies through to antibodies for microbiology. We pride ourselves on providing great customer support for all our products and services and have reliable staff on site to help with any of your antibody needs. Where are we? AbD Serotec has an ISO 9001 certified antibody production facility in Kidlington, near Oxford, UK. This facility is AbD Serotec's global headquarters, and supports our other center in Raleigh, North Carolina, USA. Our ISO 9001 certified laboratories in Puchheim, near Munich in Germany are home to our unique HuCAL custom monoclonal generation services. What can we provide for you? With antibody specialists in a range of scientific fields, AbD Serotec is able to produce and supply high quality antibodies straight to you, tailored for use with various applications including western blotting and flow cytometry. With an extensive collection of primary antibodies for studying innate immunity and having the largest range of veterinary antibodies and reagents, we empower scientists to make rewarding new discoveries. Can’t find what you need? Look no further than our custom antibody services; antibodies tailored to your needs with a wide range of antibody production and modification options. Our unique HuCAL service gives you the cutting edge of monoclonal antibody generation. A new chapter with Bio-Rad In January 2013, AbD Serotec became part of Bio-Rad Laboratories, Inc. Bio-Rad has played a leading role in the progression of scientific discovery for 60 years by providing a broad range of tools and services to the life science research and clinical diagnostics markets. With more than 7,100 employees globally, Bio-Rad are able to serve more than 100,000 research and industry customers worldwide. For more information, visit bio-rad.com. Our Mission Through innovation, 30 years of industry knowledge, and understanding our customers changing needs we will continue to build strong customer relationships and aid in advancing scientific research.

Propel Labs - Cell Sorting System Division is a automated, easy-to-use benchtop sorting flow cytometer.

QuantaLife, Inc. is a biotechnology startup focused on the development, manufacture, and marketing of innovative nucleic acid testing solutions for various markets, including life science research and clinical diagnostics. The company is pioneering a genetic analysis platform designed for medical diagnostic applications, offering advanced systems that deliver cost-effective, high-resolution capabilities. QuantaLife's proprietary technology significantly enhances the rapid detection and quantification of nucleic acids in complex samples using a flexible, automated instrument. This approach offers substantial performance improvements over existing platforms, enabling researchers to explore intricate genetic landscapes, identify new disease associations, and create enhanced molecular diagnostic tests. Currently, QuantaLife is in the early development stages, working towards transforming the field of genetic analysis.

Biotest - Businesses provides pharmaceutical, biotherapeutic, and diagnostic products.

DiaMed develops, manufactures and markets a complete line of reagents and instruments used in blood typing and screening.

Blackhawk is a manufacturer of quality control products for use in laboratories that perform infectious disease testing procedures.

Ciphergen Biosystems, Inc. is focused on the discovery, development and commercialization of high-value, molecular diagnostic products to improve patient care. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs primarily in oncology with an initial focus in ovarian and prostate cancer. Based in Fremont, California

Ciphergen Biosystems - ProteinChip Systems Business is a Enhanced Laser Desorption/ Ionization.

MJ Research, Inc. is a biotechnology company specializing in premium instruments and consumables used in modern biological research. MJ Research pioneered the use of Peltier-effect technology and has introduced a number of other innovations in the thermal-cycling field. MJ Research employs approximately 300 employees.

Quantase Ltd. is a company specializing in newborn screening diagnostic products.

Helix Diagnostics is specializing in the development and manufacture of test kits for autoimmune disease.

Bio-Rad Pasteur is a manufacturer and distributor of life science research and clinical diagnostics products. Bio-Rad Pasteur was formerly known as Pasteur Sanofi-Diagnostics.